Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”

Pfizer Inc. (NYSE:PFE) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.

Pfizer Inc. (NYSE:PFE) is one of the largest pharmaceutical companies in the world. It operates in the weight loss drug market by developing a treatment that will be administered only once a month. The shares are up by 6.7% over the past year and by 25% since Cramer discussed the firm on Mad Money. One notable movement in Pfizer Inc. (NYSE:PFE)’s shares came between September 29th and October 1st, when they gained 14%. A key announcement that occurred during this time period saw the firm announce that it would lower drug prices under Medicaid to bring them in line with those in developing countries after an agreement with President Trump and be part of the Trump administration’s TrumpRx initiative. Year-to-date, Pfizer Inc. (NYSE:PFE)’s shares are up by 7.4%. However, on February 3rd, the shares closed 3.3% lower after the firm reported its fiscal fourth quarter earnings report. The results saw Pfizer Inc. (NYSE:PFE) post $17.6 billion in revenue and $0.66 in adjusted earnings per share. Here is what Cramer had said about the firm in April 2025:

“Well, let me tell you something… right now, we have a government that is trying to figure out whether it’s going to tax the heck out of drug companies, raise tariffs outta drug companies or not. I can’t make a prediction anymore. It yields 8%. Normally I say fine, but you know what? Let’s say you decide, you know what, we need big tariffs on Pfizer. You’ll say, wow, I’m buying that stock at 18 rather than 21. So I’m going to have to say, pass.”

Piotr Kowalski/Shutterstock.com

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.